Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Trifluoperazine
Drug ID BADD_D02281
Description A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
Indications and Usage For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
Marketing Status approved; investigational
ATC Code N05AB06
DrugBank ID DB00831
KEGG ID D01448; D08636
MeSH ID D014268
PubChem ID 5566
TTD Drug ID D0R4OM
NDC Product Code Not Available
UNII 214IZI85K3
Synonyms Trifluoperazine | Trifluperazine | Trifluoroperazine | Eskazine | Flupazine | Terfluzine | Trifluoperazine Hydrochloride | Trifluoperazine HCL | Triftazin | Apo-Trifluoperazine | Apo Trifluoperazine | ApoTrifluoperazine | Stelazine
Chemical Information
Molecular Formula C21H24F3N3S
CAS Registry Number 117-89-5
SMILES CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tinnitus04.04.01.002; 17.04.07.004--
Tongue disorder07.14.01.002---
Tongue oedema07.14.02.007; 10.01.05.008; 23.04.01.009---
Torsade de pointes02.03.04.005---
Torticollis15.05.04.003; 17.01.03.003---
Tremor17.01.06.002--
Trismus15.05.04.004; 17.01.03.004--
Urinary retention20.02.02.011--
Urticaria10.01.06.001; 23.04.02.001--
Ventricular arrhythmia02.03.04.006--
Vision blurred06.02.06.007; 17.17.01.010--
Weight increased13.15.01.006--
Brain oedema12.01.10.010; 17.07.02.003--
Muscle tightness15.05.03.007---
Lupus-like syndrome10.04.03.003; 15.06.02.004; 23.03.02.004---
Musculoskeletal stiffness15.03.05.027---
Parkinsonian rest tremor17.01.05.009---
Cognitive disorder17.03.03.003; 19.21.02.001--
Eye movement disorder06.05.02.008; 17.02.05.025---
Lactation disorder18.06.02.003; 21.05.02.004--
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Blood disorder01.05.01.004---
Epinephrine abnormal13.10.01.003---
Pigmentation disorder23.05.03.001---
Liver injury09.01.07.022; 12.01.17.012---
Brain injury17.11.01.003; 19.07.03.007---
Lenticular injury06.11.01.010; 12.01.04.020---
Reduced facial expression17.01.05.016; 19.01.02.021---
The 5th Page    First    Pre   5    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene